F-Prime Capital logo

F-Prime Capital

North America, Massachusetts, United States, Cambridge

Description

F-Prime Capital is a prominent global venture capital firm with a distinctive dual focus on healthcare and technology sectors. As an affiliate of Fidelity Investments, the firm benefits from deep financial roots and a long-term investment horizon, allowing it to provide patient capital and strategic support to its portfolio companies. Headquartered in Cambridge, Massachusetts, F-Prime has established itself as a significant player in the venture ecosystem, known for its rigorous due diligence and hands-on approach.

The firm's investment strategy spans various stages, from seed to growth, with a particular emphasis on leading or co-leading early-stage rounds, including Seed, Series A, and Series B financings. Within healthcare, F-Prime targets innovative companies in biotech, medtech, and digital health, seeking to back breakthroughs that can transform patient care. In the technology realm, their interests lie in fintech, enterprise technology, and cybersecurity, identifying disruptive solutions that address critical business needs. Their global footprint allows them to source opportunities and support companies across different geographies.

F-Prime Capital is well-capitalized, having recently closed substantial funds to fuel its investment activities. In 2021, the firm announced the closing of a $500 million healthcare fund, followed by a $500 million technology fund in 2022, demonstrating significant capital deployment capacity. For typical first checks, F-Prime's initial investments generally range from approximately $2 million for seed-stage companies to $25 million or more for leading Series A or B rounds, reflecting their commitment to providing meaningful capital to accelerate growth. The firm boasts a strong track record, having invested in over 200 companies, leading to more than 50 IPOs and M&A events, underscoring their success in identifying and nurturing high-potential ventures. This strategic approach, combined with their extensive network and operational expertise, positions F-Prime Capital as a valuable partner for entrepreneurs aiming to build category-defining companies in their specialized domains.

Investor Profile

F-Prime Capital has backed more than 438 startups, with 33 new investments in the last 12 months alone. The firm has led 102 rounds, about 23% of its total and boasts 94 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, United Kingdom, China.
  • Strong thematic focus on Health Care, Biotechnology, Medical.
  • Led 6 rounds in the past year.
  • Typical check size: $2M – $25M.

Stage Focus

  • Series A (33%)
  • Series B (28%)
  • Series C (13%)
  • Seed (9%)
  • Series Unknown (8%)
  • Series D (5%)
  • Series E (1%)

Country Focus

  • United States (79%)
  • United Kingdom (6%)
  • China (5%)
  • India (3%)
  • Japan (2%)
  • Switzerland (1%)
  • Chile (1%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical
  • Therapeutics
  • Software
  • Pharmaceutical
  • Medical Device
  • Fintech
  • Financial Services
  • Information Technology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does F-Prime Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 21
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 26
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 18
Y Combinator
North America, California, United States, Mountain View
Co-Investments: 20
.406 Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 16
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 20
Maverick Ventures
North America, California, United States, San Francisco
Co-Investments: 17
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 129
Venrock
North America, California, United States, Palo Alto
Co-Investments: 16
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 33

Which angels does F-Prime Capital often collaborate with?

LW
North America, Washington, United States, Seattle
Shared Deals: 2
PS
North America, Massachusetts, United States, Boston
Shared Deals: 2
RK
North America, New York, United States, New York
Shared Deals: 3
JR
North America, California, United States, San Francisco
Shared Deals: 2
JB
North America, Massachusetts, United States, Boston
Shared Deals: 3
LG
North America, California, United States, San Francisco
Shared Deals: 5
CB
North America, Massachusetts, United States, Boston
Shared Deals: 4
ES
North America, New Jersey, United States, Princeton
Shared Deals: 2
EG
North America, California, United States, San Francisco
Shared Deals: 3
RS
North America, Washington, United States, Seattle
Shared Deals: 2

What are some of recent deals done by F-Prime Capital?

Hercle

Milano, Lombardia, Italy

Hercle is an institutional-grade infrastructure platform bridging fiat, digital assets & stablecoins for global money movement.

B2BBlockchainCryptocurrencyFinancial ServicesFinTechInfrastructure
Series UnknownOct 29, 2025
Amount Raised: $10,000,000
Limitless Labs

Grand Cayman, Midland, Cayman Islands

Limitless Labs offers a prediction-market platform that enables users to trade on short-term event outcomes using real-time asset data.

BlockchainCryptocurrencyFinanceMarketplaceSoftwareWeb3
SeedOct 20, 2025
Amount Raised: $10,000,000
ABK Biomedical

Halifax, Nova Scotia, Canada

ABK Biomedical combines the clinical market with biomaterials with a focus on treating hypervascular tumors.

BiotechnologyHealth CareMedicalMedical Device
Series DOct 14, 2025
Amount Raised: $35,000,000
Lemon Cash

Buenos Aires, Distrito Federal, Argentina

Lemon Cash is a digital wallet with FIAT and crypto capabilities.

CryptocurrencyFinTechPayments
Series BOct 10, 2025
Amount Raised: $20,000,000
Affinia Therapeutics

Waltham, Massachusetts, United States

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series COct 7, 2025
Amount Raised: $40,000,000
Kanastra

Uberlândia, Minas Gerais, Brazil

Kanastra is a platform that offers tech-driven backoffice services for alternative investments.

Asset ManagementBankingFinancial Services
Series BOct 1, 2025
Amount Raised: $30,000,000
AmplifyMD

Los Gatos, California, United States

AmplifyMD is a telemedicine platform connecting medical institutions with specialist doctors.

Health CareInformation ServicesTelehealth
Series BSep 24, 2025
Amount Raised: $20,000,000
Ensoma

Boston, Massachusetts, United States

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

BiotechnologyGeneticsLife ScienceMedicalOncologyTherapeutics
Series UnknownSep 22, 2025
Amount Raised: $53,000,000
Dispatch

Miami, Florida, United States

Dispatch helps independent financial advisors to build ideal firms through strategic investments and advanced technology.

FinanceFinancial Services
Series ASep 4, 2025
Amount Raised: $18,000,000
CHARM Therapeutics

London, England, United Kingdom

Charm Therapeutics designs and develops small-molecule therapeutics that target the interaction between menin and the KMT2A protein.

Artificial Intelligence (AI)BiotechnologyLife ScienceTherapeutics
Series BSep 2, 2025
Amount Raised: $80,000,000